Explore China's innovative drug exports surging to $91B in 2025, with mega licensing deals and policy boosts. Discover how firms like DengYueMed drive global pharma collaboration for affordable treatments.
DengYueMed is a Hong Kong-based pharmaceutical wholesaler specializing in the import and export of innovative, specialty, and rare drugs, focusing on treatments for chronic diseases, oncology, and allergies. Licensed by the Hong Kong Department of Health,...
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the official U.S. launch of Tryngolza™ (olezarsen), a novel, once-monthly RNA-targeted therapy for familial chylomicronemia syndrome (FCS).
